Utilization of anti-osteoporosis therapies increased by 41% from 2001 to 2006 before steadily declining by 63% during the next 7 years, according to an analysis of Spanish registry data.

“During the study period, the management of osteoporosis has undergone different revisions,” Elisa Martin-Merino, PhD, a senior epidemiologist at the Spanish Agency of Medicines and Medical Devices in Madrid, and colleagues wrote. “Apart from changes in the diagnostic criteria of osteoporosis itself and fracture risk-assessment strategies, modifications in the available pharmacological treatment happened.”